PROXIPART: Personalized Follow-up Program in the Type 2 Diabetes Prevention
Study Details
Study Description
Brief Summary
In France, the global prevalence of diabetes was estimated to 5% of the population in 2016, the type two diabetes (DT2) corresponding to 90% of cases. This number is widely underestimated because most people are untreated and undiagnosed. Due to the silent character of this disease, it is estimated that 20 à 30 % of diabetic adults have not yet been diagnosed. The conclusions, presented during the annual meeting of EASD in 2019, suggest that the precursor signs of this disease could be present until 20 years before the diagnosis.
Diabetes is a metabolic disease and people are diagnosed, in general, around 40-50 years old. The main risk factor of type II diabetes is lifestyle (rich diet, sedentary) but there is also other factors like hyperlipidemia, high blood pressure, high fasting blood sugar, stress, smoking, heredity, family history of diabetes, or gestational diabetes. This induces an increase of obesity, itself a major risk factor for type II diabetes occurrence.
From an economical aspect, chronic pathologies (including diabetes) represent 60% of health insurance expenses, even though it concerns 35% of insured persons, i.e. 20 million of patients. The average of annual reimbursement for a type 2 diabetic patient is 4890 euros. In this context, this study is the first step of thinking about a different, coordinated care approach, based on a preventive rather than curative approach.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This study includes a personalized care program, including the patient follow-up by a nurse during 5 years with a contact every 4 months for the first year, then after every 6 months. The nurse will review the patient's progress and provide advice and contact with professionals: physical activity, psychologists, dieticians, endocrinologists, etc The main objective of this study is to compare, after 5 years of follow-up, the risk factors associated with type 2 diabetes, between participants who received personalized follow-up and those who did not. The secondary objectives are to compare the occurrence of type 2 diabetes, the quality of life and the compliance to the program between participants who received personalized follow-up and those who did not.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: With a personalized care program The strategy implemented is a personalized care pathway that includes participant follow-up by a nurse for 5 years with contact every 4 months for the first year, then every 6 months |
Other: Personalized care program
It includes the participant follow-up by a nurse during 5 years with a contact every 4 months for the first year, then after every 6 months
|
| No Intervention: Without a personalized care program The comparison strategy does not include any specific management. The patient will not receive individualized management with the nurse coordinator. |
Outcome Measures
Primary Outcome Measures
- Risk factors for type 2 diabetes in participants [5 years]
Finnish Diabetes Risk Score (FINDRISC score) : 8 items with a total score from 0 to 26 points with 0 (no risk factor) and 26 (highest risk factor)
Secondary Outcome Measures
- Diabetes diagnostic [at 5 years]
measuring fasting blood glucose
- The Quality of Life [at 5 years]
WHO questionary : total score out of 100, 26 questions with 5 likert scale items
- program compliance [during 5 years]
Compliance is based on all the scheduled visits, the number of visits not carried out and the time during the research will be described in each group.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Person with a FINDRISC score ≥ 10 points
-
Person who has given his/her express written and informed consent
Exclusion Criteria:
- Person already diagnosed with a type 2 diabetes
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Investigators
- Principal Investigator: Aurelie LIETAER, MD, Clinique Aguilera-RGDS
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2021-A00375-36